Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in mAbs
- Vol. 13 (1) , 1981202
Abstract
Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). Bemarituzumab is being developed as a cancer therapeutic, and we summarize here the key nonclinical data that supported moving it into clinical trials. Bemarituzumab displayed sub-nanomolar cross-species affinity for FGFR2b receptors, with >20-fold enhanced binding affinity to human Fc gamma receptor IIIa compared with the fucosylated version. In vitro, bemarituzumab induced potent ADCC against FGFR2b-expressing tumor cells, and inhibited FGFR2 phosphorylation and proliferation of SNU-16 gastric cancer cells in a concentration-dependent manner. In vivo, bemarituzumab inhibited tumor growth through inhibition of the FGFR2b pathway and/or ADCC in mouse models. Bemarituzumab demonstrated enhanced anti-tumor activity in combination with chemotherapy, and due to bemarituzumab-induced natural killer cell-dependent increase in programmed death-ligand 1, also resulted in enhanced anti-tumor activity when combined with an anti-programmed death-1 antibody. Repeat-dose toxicity studies established the highest non-severely-toxic dose at 1 and 100 mg/kg in rats and cynomolgus monkeys, respectively. In pharmacokinetic (PK) studies, bemarituzumab exposure increase was greater than dose-proportional, with the linear clearance in the expected dose range for a mAb. The PK data in cynomolgus monkeys were used to project bemarituzumab linear PK in humans, which were consistent with the observed human Phase 1 data. These key nonclinical studies facilitated the successful advancement of bemarituzumab into the clinic.Keywords
Funding Information
- not funded
This publication has 38 references indexed in Scilit:
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targetsGut, 2012
- FGFR2 gene amplification and clinicopathological features in gastric cancerBritish Journal of Cancer, 2012
- Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor XenograftsClinical Cancer Research, 2010
- Signaling by FGFR2b controls the regenerative capacity of adult mouse incisorsDevelopment, 2010
- Population Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisitedBiopharmaceutics & Drug Disposition, 2010
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 2010
- Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial LookThe Journal of Clinical Pharmacology, 2009
- FGFR2 in the dental epithelium is essential for development and maintenance of the maxillary cervical loop, a stem cell niche in mouse incisorsDevelopmental Dynamics, 2009
- Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signalingDevelopmental Biology, 2008